CN103877413B - A kind of pharmaceutical composition treating Oral diseases - Google Patents
A kind of pharmaceutical composition treating Oral diseases Download PDFInfo
- Publication number
- CN103877413B CN103877413B CN201410101719.4A CN201410101719A CN103877413B CN 103877413 B CN103877413 B CN 103877413B CN 201410101719 A CN201410101719 A CN 201410101719A CN 103877413 B CN103877413 B CN 103877413B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- oral diseases
- arachidis hypogaeae
- active component
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition treating Oral diseases, said composition comprises active component and pharmaceutic adjuvant, and described active component is that after being mixed with Pericarppium arachidis hypogaeae by Radix Oryzae Glutinosae, water carries and obtains.The pharmaceutical composition of the present invention acts on cheek mucosa fibroblasts, can promote this cell proliferation, considerably increases this cell repair ability to lesion region, accelerates the healing of pathological changes.
Description
Technical field
The invention belongs to pharmaceutical technology field, in particular to a kind of Chinese medicine extract, particularly relate to one and treat mouth
The pharmaceutical composition of chamber mucosa lichen planus.
Background technology
Oral lichen planus (oral lichenplanus, OLP) is the struvite of a kind of agnogenic T cell mediation
Skin, mucous membrane disease, be one of oral mucosa commonly encountered diseases.Modern medicine is also to the oral lichen planus cause of disease the most clearly, it is believed that
May be with Nervous and Mental Factors, infection, medicine, chronic lesion, systemic disease, enzyme exception, cryptorrhea or qi depression to blood stasis etc.
Relevant.This disease is apt to occur in middle age, and women is more than male.Current local therapeutic approaches includes antibiotic solution rinsing the mouth, infringement
Interior injection or external glucocorticoid, 0.1% tretinoin ointment.But long-term external glucocorticoid often produces local atrophy, sense
The untoward reaction such as dye, telangiectasis, the curative effect of antibiotic solution rinsing the mouth and 0.1% tretinoin ointment is the most undesirable.
Sum it up, there is no the highly effective medicine for oral lichen planus at present clinically, therefore, find
Effective medicine of intervening has very important theory significance and using value.
Summary of the invention
The present inventor is prepared for a kind of water extract lyophilized powder according to folk prescription among the people, and this medicament freeze-drying powder gives rat filling
Contained Serum is obtained, surprisingly, Contained Serum can promote that rat cheek mucosa fibroblasts quickly rises in value after stomach.
Based on above-mentioned discovery, it is an object of the invention to provide a kind of pharmaceutical composition treating Oral diseases.
The object of the present invention is achieved like this:
A kind of pharmaceutical composition treating Oral diseases, comprises active component and pharmaceutic adjuvant, described work
Property composition is that after being mixed with Pericarppium arachidis hypogaeae by Radix Oryzae Glutinosae, water carries and obtains.
Preferably, treating the pharmaceutical composition of Oral diseases as mentioned above, wherein said active component is
Radix Oryzae Glutinosae is carried by weight water after mixing for 3-6:1 with Pericarppium arachidis hypogaeae and obtains.
It is further preferred that treat the pharmaceutical composition of Oral diseases, wherein said activity as mentioned above
Composition is to be carried by weight water after mixing for 5:1 with Pericarppium arachidis hypogaeae by Radix Oryzae Glutinosae and obtain.
The most preferably, treating the pharmaceutical composition of Oral diseases as mentioned above, wherein said water carries
Method be: after dry Radix Oryzae Glutinosae is mixed with Pericarppium arachidis hypogaeae with alcohol heating reflux extract, filter, filtrate discard after residue medicine
Slag, add water heating and refluxing extraction, refilters, filtrate concentrate drying.
The pharmaceutical composition for the treatment of Oral diseases of the present invention can be made into oral formulations, described mouth
Formulation is granule, tablet, capsule.
It should be noted that Radix Oryzae Glutinosae of the present invention selects grass family oryza plant Oryza sativa L. var. glutinosa Matsum. Oryza sativa
The dry root stock of L.var.glutinosa Matsum. and fibrous root；Pericarppium arachidis hypogaeae selects pulse family Arachis plant Semen arachidis hypogaeae
The pod shell of Arachis hypogaea L. fruit.
Compared with prior art, the invention have the advantages that and marked improvement: the pharmaceutical composition of the present invention acts on
Rat cheek mucosa fibroblasts, can promote this cell proliferation, considerably increases this cell repair ability to lesion region,
Accelerate the healing of pathological changes.Observation indicate that in clinical practice, Chinese medicine lichen mixture treatment lichen planus, curative effect is full
Meaning, side effect is little, has safe, lasting, stable feature, the work play and regulate overall health of patients, improving and eliminating local disease damage
With.
Specific embodiment
The present invention is further described below by way of detailed description of the invention.Owing to describing according to preferred embodiment below
The present invention, the most any equivalent will be apparent from for the ordinary skill in the art, and is included in this
Among invention.
Embodiment 1
Being dried Radix Oryzae Glutinosae 1.2kg and Pericarppium arachidis hypogaeae 0.2kg, 80% alcohol heating reflux adding 20L extracts 2h, filters, discards
Filtrate, adds 80% ethanol of 15L, heating and refluxing extraction 1.5h, filters, discard filtrate in filtering residue, add 20L pure water in filtering residue
It is heated to reflux extracting respectively 2 times, is concentrated into paste, lyophilization evacuation after merging filtrate, obtains lyophilized powder.
Embodiment 2
Being dried Radix Oryzae Glutinosae 1.2kg and Pericarppium arachidis hypogaeae 0.4kg, 85% alcohol heating reflux adding 22L extracts 2h, filters, discards
Filtrate, adds 85% ethanol of 16L, heating and refluxing extraction 1.5h, filters, discard filtrate in filtering residue, add 20L pure water in filtering residue
It is heated to reflux extracting respectively 2 times, is concentrated into paste, lyophilization evacuation after merging filtrate, obtains lyophilized powder.
Embodiment 3
Being dried Radix Oryzae Glutinosae 1.2kg and Pericarppium arachidis hypogaeae 0.24kg, 80% alcohol heating reflux adding 20L extracts 2h, filters, abandons
Fall filtrate, filtering residue adds 80% ethanol of 15L, heating and refluxing extraction 1.5h, filters, discard filtrate, filtering residue adds 20L pure
Water is heated to reflux extracting respectively 2 times, is concentrated into paste, lyophilization evacuation, obtains lyophilized powder after merging filtrate.
The impact that cheek mucosa fibroblasts is bred by embodiment 4 Radix Oryzae Glutinosae Pericarppium arachidis hypogaeae water extract
Taking 6 week old SD male rat 6, after 3% pentobarbital sodium (1ml/kg) anesthesia, iodophor disinfection cheek mucosa, in cheek
Fusiform incision at mucosa, takes 0.2cm × 0.2cm size lining mucosa lamina propria tissue, put into 4 DEG C of pre-coolings containing 1000 μ g/ml
Penicillin, 500 μ g/ml streptomycin PBS clean 2 times.The piece of tissue of separation is cut into 0.5mm in little plate3Size, adds
The DMEM of the 10%FBS of 5ml, blows and beats dispersion tissue's block with suction pipe, and piece of tissue and culture fluid are together moved into 25cm2Culture bottle
In, piece of tissue is uniformly distributed in culture bottle, puts 37 DEG C, 5%CO2CO2 gas incubator in cultivate, after 4d the 1st time see
Examining and change liquid, remove the most adherent floating tissue, within the most every 3 days, change liquid 1 time, until at the bottom of cell confluent cultures bottle time, row passes on training
Support.
Fibroblast Secondary Culture: sucked by culture fluid with suction pipe, adds Digestive system (0.25% Trypsin in culture bottle
Enzyme and 0.02%EDTA1:3) 2ml, jiggles culture bottle, makes Digestive system be fully contacted cell, digest 2min, be inverted at 37 DEG C
See under phase contrast microscope that intercellular substance becomes big, volume becomes round, cell space brightens under mirror, and the DMEM adding 10%FBS stops digestion, inhales
Pipe is blown and beaten gently, carries out sub-bottle and passes on.SABC carries out cell vimentin and anti-cytokeratin Ab fluorescence staining, does
Cell derived is identified, it is positive immunostaining that result is shown as fibrocyte vimentin, cell cytosol coloring (brown), karyon
Not colored.Keratin is Negative immunostaining, and endochylema karyon is the most not colored, illustrates to cultivate cell for deriving from mesoblastic one-tenth fiber
Cell.Six orifice plates are put coverslip, cell climbing sheet (24h)；70% ethanol fixes 30min, PBS 2min；0.1%
TritonX-100 soaks 20min；PBS 3 times, each 2min；3% hydrogen peroxide incubated at room lOmin；10% normal Sanguis caprae seu ovis
Clear incubated at room 10min；Outwelling one anti-(1:100) of serum dropping PBS dilution, 4 DEG C of wet boxes hatch 12h；PBS 3 times, often
Secondary 2min；The two of dropping FITC labelling goat antirabbit resist, and 4 DEG C of wet boxes hatch 12h；PBS 3 times, each 2min；Glycerol seals
Sheet, microscopy.
Experiment is divided into Contained Serum group and without medicine serum group.Contained Serum group serum is from 6 continuous 7d gastric infusions
SD rat, test medicine is the water extract lyophilized powder of the embodiment of the present invention 3 preparation, and dosage is 80mg/kg/d, every day one
Secondary, last day interval 2h is administered again, 1h ventral aorta blood sampling after last is administered, and centrifugal 3000r/min, 20min take
Clearly, the degerming rear subpackage of bacteria filter (0.20 μm) sucking filtration ,-20 DEG C save backup.The serum of serum group without medicine, from 6 SD rats, is given
Give equivalent pure water alternatives to medication to prepare as stated above without medicine serum.
By the 4th generation rat cheek mucosa fibroblasts through trypsinization, counted under microscope, adjusting cell density is
5×108/ L, every hole 100 μ L are inoculated in 96 porocyte culture plates, 37 DEG C, 5%CO2Incubator is cultivated 2d, sets according to experiment
Culture fluid is replaced as above two serum by meter to be continued to cultivate, and often the multiple hole of group 6 cultivates 24h, 48h, 72h, each Kong Zhongjia respectively
Entering 5mg/mL MTT20 μ L, continue to cultivate 4h sucking-off supernatant, add lO0 μ L dimethyl sulfoxide in every hole, shaking table vibration 15min makes
Crystallization is fully dissolved, with the every porocyte absorbance measuring 490nm on enzyme linked immunological tester.
Result of the test according to table 1 is it can be seen that rat cheek mucosa fibroblasts is respectively at pastille with without in medicine serum
After cultivation, cellular morphology is identical, and two groups of cells gradually increase along with the prolongation of incubation time, cell quantity, and Contained Serum group increases
Add more significantly, statistically significant with without medicine serum group difference.
After table 1 rat cheek mucosa fibroblasts is cultivated in two kinds of serum, cell proliferative conditions compares
Compare with without medicine serum group,*P ＜ 0.05；Compare with without medicine serum group,**P ＜ 0.01.
Claims (3)
1. treat a pharmaceutical composition for Oral diseases, be made up of active component and pharmaceutic adjuvant, wherein said
Active component be Radix Oryzae Glutinosae and Pericarppium arachidis hypogaeae to be carried by weight water after mix for 5:1 and obtain, the method that described water carries is: general does
Dry Radix Oryzae Glutinosae mix with Pericarppium arachidis hypogaeae after with alcohol heating reflux extract, filter, filtrate discard after residue medicinal residues, add water and heat back
Stream extracts, and refilters, filtrate concentrate drying.
Treat the pharmaceutical composition of Oral diseases, wherein said pharmaceutical composition the most according to claim 1
It it is oral formulations.
The most according to claim 2, treat the pharmaceutical composition of Oral diseases, wherein said oral formulations is
Granule, tablet, capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410101719.4A CN103877413B (en) | 2014-03-19 | 2014-03-19 | A kind of pharmaceutical composition treating Oral diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410101719.4A CN103877413B (en) | 2014-03-19 | 2014-03-19 | A kind of pharmaceutical composition treating Oral diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103877413A CN103877413A (en) | 2014-06-25 |
| CN103877413B true CN103877413B (en) | 2016-12-07 |
Family
ID=50946749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410101719.4A Expired - Fee Related CN103877413B (en) | 2014-03-19 | 2014-03-19 | A kind of pharmaceutical composition treating Oral diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103877413B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160017607A (en) * | 2014-08-05 | 2016-02-16 | 전남대학교산학협력단 | Oral anti-atopic preparations comprising rice prolamin |
-
2014
- 2014-03-19 CN CN201410101719.4A patent/CN103877413B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103877413A (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ623454A (en) | Pharmaceutical composition for the treatment of heart diseases | |
| TWI598104B (en) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
| CN109985055B (en) | Pharmaceutical composition for resisting cerebral ischemia reperfusion injury and application thereof | |
| CN107375474B (en) | Vitiligo vitamine compound and preparation method thereof | |
| CN103877413B (en) | A kind of pharmaceutical composition treating Oral diseases | |
| Ma et al. | Puerarin action on stem cell proliferation, differentiation and apoptosis: Therapeutic implications for geriatric diseases | |
| CN109045035A (en) | Application of 7- (2,2- dimethyl -3- crotonoyl the amido)-octahydro benzene quinoline acetic acid esters in preparation treatment liver disease drug | |
| CN102526423A (en) | Medicine composition for treating ischemic heart disease | |
| CN102764294B (en) | Cough relieving and sputum eliminating combination and preparation method thereof | |
| CN103301217A (en) | Composition and applications thereof, pharmaceutical preparation and health-care product | |
| CN102805743A (en) | Application of arctigenin in treating angiogenesis diseases | |
| CN102670583A (en) | Application of flavonoids in moldavica dragonhead in the preparation of myocardial ischemic antagonist | |
| CN115025137A (en) | External traditional Chinese medicine extract for promoting wound healing and extraction method and application thereof | |
| CN106377537B (en) | Application of acetyl astragaloside | |
| CN103251869B (en) | Traditional Chinese medicinal psoralen-containing composition for treating stomach cancer and preparation method and application thereof | |
| CN105343109A (en) | Application of cycloastragenol in preparation of drugs for protecting liver and promoting liver injury restoration | |
| CN106924448B (en) | Pharmaceutical composition for treating wind-heat type common cold and preparation method thereof | |
| CN110327317A (en) | Application of the alkannin in the drug for preparing anti-rotavirus infection | |
| CN104161799B (en) | Compound red sage root extract and its preparing method | |
| CN117442603B (en) | Application of schaftoside in preparation of heart failure resistant medicines | |
| TWI533876B (en) | An herbal composition against uterine fibroid and a use of its extract thereof | |
| CN115844933B (en) | Application of clindamycin total flavone in preparing heart failure resisting medicine | |
| CN102526461A (en) | Application of traditional Chinese medicine composition in preparing medicament for resisting myocardial cell hypoxic injury | |
| CN106924326A (en) | A kind of horizontal root takes dish extract and its production and use | |
| CN106727495A (en) | Application of the one class flavanone compound in myocardial preservation medicine is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161207 Termination date: 20180319 |